Treatment of COVID-19: old tricks for new challenges

Abstract

Challenges in treating COVID-19Coronavirus disease (COVID-19), which appeared in December 2019, presents a global challenge, particularly in the rapid increase of critically ill patients with pneumonia and absence of definitive treatment.To date, over 81,000 cases have been confirmed, with over 2700 deaths.The mortality appears to be around 2%; early published data indicate 25.9% with SARS-CoV-2 pneumonia required ICU admission and 20.1% developed acute respiratory distress syndrome [1].There is presently no vaccine or specific anti-viral drug regime used to treat critically ill patients.The management of patients mainly focuses on the provision of supportive care, e.g., oxygenation, ventilation, and fluid management.Combination treatment of low-dose systematic corticosteroids and anti-virals and atomization inhalation of interferon have been encouraged as part of critical COVID-19 management [2].Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1.

Cited by papers we hold 5

• Fostering Resilient Health Systems in India: Providing Care for PLHIV Under the Shadow of COVID-19 · 2022
  Not checked
• Impact of repurposed drugs on the symptomatic COVID-19 patients · 2021
  Not checked
• Predicting Perceived Stress Related to the Covid-19 Outbreak through Stable Psychological Traits and Machine Learning Models · 2020
  No notice
• Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future · 2020
  No notice
• Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.